Brainstorm cell therapeutics announces second quarter 2023 financial results and provides corporate update

Fda advisory committee (adcom) meeting to discuss nurown® for amyotrophic lateral sclerosis (als) scheduled for september 27, 2023 brainstorm's biologics license application (bla) for nurown has a prescription drug user fee act (pdufa) action date targeted to occur by december 8, 2023 company prepares for adcom date presentation and builds resources for fda review and decision conference call and webcast at 8:00 a.m. eastern time today new york , aug. 14, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended june 30, 2023 and provided a corporate update.
BCLI Ratings Summary
BCLI Quant Ranking